IGHE and allergic disease: Parallel to both these observations and other reports of the impact of allergy medication, such as antihistamines, on cancer risk, there has been investigation into whether use of the anti-IgE therapeutic omalizumab may present increased cancer risk, with accompanying FDA drug information indicating such concerns [110].